Filing Analysis
Aldeyra Therapeutics entered into a new office lease agreement for corporate headquarters space in Concord, Massachusetts. The lease term runs from September 1, 2026, through September 30, 2029.
📋 Key Facts
- Lease signed on July 28, 2026, with Bradford Street, L.L.C.
- Premises: 4,067 square feet at 23 Bradford Street, Concord, MA.
- Term: September 1, 2026, to September 30, 2029 (approx. 3 years).
- Monthly Base Rent: $12,201.00 (subject to annual increases).
- Security Deposit: $50,000.00.
- Purpose: To serve as the company's corporate headquarters.
Aldeyra Therapeutics reported receiving meeting minutes from the FDA regarding a Type A meeting held on June 10, 2026, concerning the potential resubmission of its New Drug Application (NDA) for reproxalap. The company is seeking clarification on these minutes and plans to request a Type D meeting with the FDA by the end of Q3 2026.
🚩 Red Flags
- The need for clarification on FDA minutes and the requirement for a Type D meeting suggests that the previous NDA submission path may have encountered regulatory hurdles or complexities requiring further alignment with the FDA.
📋 Key Facts
- Type A meeting held with the FDA on June 10, 2026, regarding reproxalap NDA resubmission for dry eye disease.
- Company requested clarification of the FDA meeting minutes on July 15, 2026.
- Aldeyra intends to request a Type D meeting with the FDA to discuss potential NDA resubmission.
- Type D meeting is expected to occur by the end of Q3 2026.
Aldeyra Therapeutics reported the results of its 2026 Annual Meeting of Stockholders, including the election of a director and the ratification of its auditor. The company also appointed Darlene Deptula-Hicks as a Class III director and Chair of the Audit Committee.
📋 Key Facts
- Darlene Deptula-Hicks appointed as Class III director and Chair of the Audit Committee on June 9, 2026.
- Ms. Deptula-Hicks is designated as an audit committee financial expert.
- Compensation for Ms. Deptula-Hicks includes a grant of 94,313 stock options, an annual director fee of $40,000, and an Audit Committee Chair fee of $7,500.
- Stockholders ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm for fiscal year 2026.
- Todd C. Brady, M.D., Ph.D. was elected as a Class III director.
- Executive compensation was approved on a non-binding advisory basis.
- Quorum was established with 44,271,484 shares represented (approx. 73.4% of entitled shares).
Aldeyra Therapeutics released an updated corporate presentation detailing clinical efficacy data and FDA positioning for its reproxalap New Drug Application (NDA) for dry eye disease. The filing specifically highlights the company's interpretations of FDA stances on primary endpoints compared to its own positions.
🚩 Red Flags
- Potential disagreement or differing interpretations between the FDA and the company regarding primary clinical endpoints for reproxalap, which could impact approval timelines.
📋 Key Facts
- Released updated corporate overview presentation on May 1, 2026.
- Disclosed standardized treatment estimates and confidence intervals for primary endpoints of reproxalap efficacy clinical trials.
- Included abbreviated interpretations of U.S. Food & Drug Administration (FDA) positions on primary endpoints.
- Contrasted Aldeyra's positions with the FDA's positions regarding the dry eye disease NDA data.
Aldeyra Therapeutics announced that director Martin J. Joyce will not stand for re-election at the 2026 annual meeting of stockholders. Mr. Joyce will continue to serve on the board until his current term expires at the meeting.
📋 Key Facts
- Notification date: April 20, 2026
- Director: Martin J. Joyce
- Event: Decision not to stand for re-election at the 2026 Annual Meeting
- Company stated the decision was not the result of any disagreement
- Mr. Joyce will serve until the 2026 Annual Meeting
Aldeyra Therapeutics paid off its $15 million outstanding debt under the Hercules Credit Facility on its maturity date of April 1, 2026. The facility was terminated, and the company reiterated its cash runway expectations into 2028.
📋 Key Facts
- Paid off $15 million in outstanding borrowings on April 1, 2026.
- Terminated the Loan and Security Agreement with Hercules Capital, Inc. (originally dated March 25, 2019).
- Company expects cash, cash equivalents, and marketable securities as of December 31, 2025, to support operations into 2028.
Aldeyra Therapeutics received a second Complete Response Letter (CRL) from the FDA regarding its New Drug Application for reproxalap for the treatment of dry eye disease. The FDA cited a lack of substantial evidence of efficacy and expressed serious concerns regarding the reliability of positive findings due to inconsistent study results.
🚩 Red Flags
- Receipt of a second CRL for the same lead drug candidate.
- FDA language questioning the 'reliability and meaningfulness' of the company's positive clinical findings.
- History of regulatory delays, including a PDUFA extension in December 2025 and a previous CRL in April 2025.
📋 Key Facts
- The 2026 CRL stated the application failed to demonstrate efficacy in adequate and well-controlled studies.
- The FDA noted that the 'totality of evidence from the completed clinical trials does not support the effectiveness of the product.'
- This is the second CRL for reproxalap, following a previous rejection in April 2025.
- No safety or manufacturing concerns were identified by the FDA.
- The FDA did not explicitly recommend additional trials but suggested identifying specific populations where the drug may be effective.
- The company reported cash, cash equivalents, and marketable securities as of December 31, 2025, are expected to support operations into 2028.
Aldeyra Therapeutics announced the voluntary resignation of Chief Development Officer Stephen G. Machatha, Ph.D., effective on or before March 31, 2026. The departure is intended to be a smooth transition with a structured separation agreement in place.
🚩 Red Flags
- Departure of a key executive (Chief Development Officer) in the biotech sector can impact clinical development timelines or institutional knowledge transfer.
📋 Key Facts
- Stephen G. Machatha, Ph.D. resigned as Chief Development Officer on December 23, 2025.
- The resignation is voluntary and not due to any disagreement regarding company operations or financial reporting.
- Separation Date is scheduled for on or before March 31, 2026.
- A Transition Agreement includes a lump sum payment of $88,000 (50% of potential 2025 bonus) upon execution.
- An additional $88,000 may be paid if an additional release of claims is executed after the Separation Date.
Aldeyra Therapeutics announced that the FDA has extended the PDUFA date for its topical ocular reproxalap, an investigational drug for dry eye disease. This delay in the regulatory decision timeline is communicated via a Regulation FD disclosure and press release.
🚩 Red Flags
- Regulatory delay: The extension of a PDUFA date represents a setback in the anticipated timeline for product approval and potential commercialization.
📋 Key Facts
- The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for topical ocular reproxalap.
- Reproxalap is intended for the treatment of signs and symptoms of dry eye disease.
- The company scheduled a conference call for December 16, 2025, to discuss the announcement.
Aldeyra Therapeutics issued an 8-K to announce its 2025 Research & Development Webcast. The filing includes a slide presentation and a press release detailing R&D updates, specifically regarding the expansion of their RASP platform into central nervous system diseases and manufacturing updates for reproxalap.
🚩 Red Flags
- Standard forward-looking statement risk disclosures regarding clinical trial success and regulatory approval.
📋 Key Facts
- Company held/announced a 2025 Research & Development Webcast on November 13, 2025.
- Announced expansion of the RASP modulator platform to include central nervous system (CNS) diseases.
- Provided manufacturing updates for reproxalap, an investigational drug for dry eye disease.
- The filing includes Exhibit 99.1 (Slide Presentation) and Exhibit 99.2 (Press Release).
Aldeyra Therapeutics announced positive Phase 2 clinical trial results for alcohol-associated hepatitis and provided an update on their RASP modulator product pipeline. The company also reported an extension of its projected operational cash runway into the second half of 2027.
📋 Key Facts
- Positive Phase 2 clinical trial results in alcohol-associated hepatitis announced on October 28, 2025.
- Prioritization of RASP modulator product candidates within the company's pipeline.
- Operational cash runway extended into the second half of 2027.
Aldeyra Therapeutics announced that the FDA has granted Fast Track Designation for its drug candidate ADX-2191 for the treatment of retinitis pigmentosa. This regulatory milestone is intended to facilitate the development and expedite the review process for this therapeutic candidate.
📋 Key Facts
- FDA granted Fast Track Designation for ADX-2191 on August 19, 2025.
- The designation is specifically for the treatment of retinitis pigmentosa.
- Fast Track Designation is intended to facilitate development and expedite review of drugs that treat serious conditions and fill unmet medical needs.
Aldeyra Therapeutics announced that the FDA has accepted its resubmitted New Drug Application (NDA) for reproxalap to treat dry eye disease. The FDA has assigned a PDUFA target action date of December 16, 2025.
📋 Key Facts
- FDA accepted the resubmitted NDA for reproxalap (investigational drug for dry eye disease) for review.
- PDUFA target action date is set for December 16, 2025.
- The filing includes a press release as Exhibit 99.1.
Aldeyra Therapeutics announced receipt of a Special Protocol Assessment (SPA) from the FDA regarding its investigational drug candidate, ADX-2191, for treating primary vitreoretinal lymphoma (PVRL). This regulatory milestone provides agreement on the clinical trial design required to support a future marketing application.
📋 Key Facts
- Received Special Protocol Assessment (SPA) from the FDA on June 26, 2025.
- The SPA pertains to ADX-2191 for the treatment of primary vitreoretinal lymphoma (PVRL).
- An SPA indicates agreement between the FDA and the sponsor on the design of a clinical trial to support a regulatory submission.
Aldeyra Therapeutics announced the resubmission of a New Drug Application (NDA) to the FDA for its investigational drug candidate, topical ocular reproxalap, intended for treating dry eye disease.
📋 Key Facts
- Resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).
- The application is for topical ocular reproxalap.
- Target indication: treatment of signs and symptoms of dry eye disease.
- Announcement date: June 17, 2025.
Aldeyra Therapeutics held its 2025 annual meeting of stockholders on June 10, 2025. The filing reports the results of shareholder votes regarding director elections, auditor ratification, and executive compensation.
📋 Key Facts
- Annual Meeting held on June 10, 2025.
- Quorum reached with 45,618,769 shares (approx. 76.2%) represented out of 59,895,588 total shares entitled to vote.
- Three Class II directors were elected: Richard H. Douglas, Gary M. Phillips, and Neal S. Walker.
- BDO USA, P.C. was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2025.
- Shareholders approved executive compensation on a non-binding advisory basis.
Aldeyra Therapeutics announced that its Phase 3 trial for reproxalap ophthalmic solution met the primary endpoint of ocular discomfort in patients with dry eye disease. Consequently, the company plans to resubmit a New Drug Application (NDA) for the candidate.
📋 Key Facts
- Achieved primary endpoint of ocular discomfort in Phase 3 dry eye chamber trial.
- Drug candidate: 0.25% reproxalap ophthalmic solution.
- Indication: Treatment of dry eye disease.
- Company plans to resubmit a New Drug Application (NDA).
- Announcement made via press release on May 5, 2025.
Aldeyra Therapeutics, Inc. announced the election of William (Chip) Clark to its Board of Directors as a Class I director. The appointment includes an increase in the total number of directors to eight.
📋 Key Facts
- William (Chip) Clark elected as a Class I director on April 17, 2025.
- The Board increased the total number of directors to eight.
- Mr. Clark was granted non-statutory stock options for 76,760 shares, vesting ratably over three years.
- Annual director fee set at $40,000.
- Eligible for annual stock option grants valued at approximately $130,000 following each annual meeting of stockholders.
Aldeyra Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its resubmitted New Drug Application for reproxalap, intended to treat dry eye disease. The FDA cited insufficient evidence of efficacy and requested at least one additional well-controlled study due to methodological concerns in existing data.
🚩 Red Flags
- Regulatory setback: Failure of a resubmitted NDA is a significant blow to a biotech's primary asset pipeline.
- Requirement for additional clinical trials increases cash burn and delays potential commercialization.
- Methodological concerns raised by FDA regarding baseline score differences suggest data integrity or study design issues.
📋 Key Facts
- FDA issued a Complete Response Letter (CRL) on April 3, 2025, regarding the resubmitted NDA for reproxalap.
- The FDA stated the NDA failed to demonstrate efficacy in treating ocular symptoms of dry eye disease.
- Methodological issues were identified, specifically differences in baseline scores across treatment arms in submitted trials.
- FDA requires at least one additional adequate and well-controlled study to demonstrate positive effect on ocular symptoms.
- The company expects to announce results from two ongoing dry eye disease trials in Q2 2025.
- Aldeyra intends to resubmit the NDA mid-year 2025, pending positive trial results and FDA discussions.
Aldeyra Therapeutics entered into an extension side letter with AbbVie Inc. regarding an existing Exclusive Option Agreement and announced that the FDA has accepted its resubmitted NDA for reproxalap, with a PDUFA date of April 2, 2025.
🚩 Red Flags
- If AbbVie does not exercise the option, Aldeyra remains solely responsible for all launch activity costs incurred.
- Regulatory risk: The outcome of the NDA resubmission is subject to FDA review by April 2025.
📋 Key Facts
- Entered into an Extension Letter with AbbVie Inc. on November 15, 2024.
- The agreement allows Aldeyra to conduct launch activities (costs not to exceed mid-single-digit millions without AbbVie approval) that are 60% reimbursable by AbbVie if the option is exercised.
- AbbVie has independently initiated pre-commercialization planning activities.
- The Exercise Period for AbbVie's option is now ten (10) business days following FDA Approval of reproxalap.
- FDA accepted resubmitted NDA for reproxalap (dry eye disease treatment); PDUFA date set for April 2, 2025.
Aldeyra Therapeutics announced the resubmission of a New Drug Application (NDA) to the FDA for topical ocular reproxalap, intended for the treatment of dry eye disease. This represents a significant regulatory milestone in the company's clinical development pipeline.
📋 Key Facts
- Company resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).
- The application is for topical ocular reproxalap, an investigational new drug candidate.
- Target indication: treatment of signs and symptoms of dry eye disease.
- Filing date: October 3, 2024.
Aldeyra Therapeutics entered into a Fourth Amendment to its Loan and Security Agreement with Hercules Capital, Inc. The amendment extends the maturity date and interest-only payment period but includes an increased interest rate floor.
🚩 Red Flags
- Extension of debt maturity suggests a need for additional runway to reach liquidity milestones.
- Interest rate floor set at 11.10% indicates high cost of capital typical of distressed or high-risk micro-cap biotech lending.
- Requirement of a $300,000 supplemental end of term charge.
📋 Key Facts
- Entered into Fourth Amendment to Loan and Security Agreement on September 30, 2024.
- Extends interest-only payment period from October 1, 2024, to April 1, 2026.
- Extends Term Loan Maturity Date from October 1, 2024, to April 1, 2026.
- Amended interest rate is the greater of Prime Rate + 3.10% or 11.10%.
- A supplemental end of term charge of $300,000 is due upon maturity, repayment, or acceleration.
Aldeyra Therapeutics announced a leadership transition in its finance department, appointing Michael Alfieri as Principal Financial Officer and Principal Accounting Officer via an outsourcing arrangement with Danforth Global, Inc. This follows the departure of Bruce Greenberg from his roles as SVP of Finance and Interim CFO.
🚩 Red Flags
- Transition from an in-house CFO/PFO to an outsourced model (Danforth Global, Inc.) can sometimes indicate cost-cutting or a temporary gap in permanent leadership.
- The use of a consulting firm for core financial officer roles is common in micro-caps but represents a shift in internal structure.
📋 Key Facts
- Michael Alfieri appointed as PFO and PAO effective August 31, 2024.
- Mr. Alfieri will serve via a Master Services Agreement with Danforth Global, Inc. as an independent contractor.
- Bruce Greenberg stepped down from SVP of Finance, Interim CFO, and PFO/PAO roles effective August 31, 2024.
- Greenberg's separation package includes 6 months of base salary, a $125,895 lump-sum payment, and 6 months of COBRA premiums.
- Greenberg will remain as a consultant through November 30, 2024, to facilitate the continued vesting of his outstanding stock options.
Aldeyra Therapeutics announced that its Phase 3 clinical trial for reproxalap ophthalmic solution (for dry eye disease) successfully achieved its primary endpoint of reducing ocular discomfort. The company is hosting a conference call to discuss these results.
📋 Key Facts
- Achieved the primary endpoint in the Phase 3 dry eye chamber clinical trial.
- The drug candidate is 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease.
- Announcement made via press release and supplemental presentation on August 8, 2024.
Aldeyra Therapeutics entered into a new Open Market Sale Agreement with Jefferies LLC to facilitate the 'at-the-market' (ATM) sale of up to $75,000,000 in common stock. This agreement replaces a previous sales agreement that had expired.
🚩 Red Flags
- Potential for significant shareholder dilution through the issuance of new common stock.
- ATM offerings are often used by micro-cap biotech companies to bolster cash runways, which can signal immediate liquidity needs.
📋 Key Facts
- Entered into a new Open Market Sale Agreement with Jefferies LLC on August 1, 2024.
- The agreement allows for the sale of up to $75,000,000 of common stock via 'at-the-market' methods.
- Jefferies LLC will receive an aggregate compensation of up to 3.0% of the gross sales price per share.
- The company has no obligation to sell any shares under this agreement and can suspend or terminate it at its discretion.
- Replaces a prior $100,000,000 Sales Agreement that expired on April 15, 2024.
Aldeyra Therapeutics issued an 8-K to announce the advancement of new RASP modulators and recent preclinical data regarding obesity. The company also scheduled a virtual Investor Roundtable for June 20, 2024, to discuss these developments.
📋 Key Facts
- Announced advancement of new RASP (Retinoic Acid Receptor-related) modulators.
- Released recent preclinical data specifically related to obesity treatments.
- Held a virtual Investor Roundtable on June 20, 2024, to discuss the press release and other topics.
Aldeyra Therapeutics announced the completion of enrollment for its Phase 3 clinical trial of topical ocular 0.25% reproxalap, an investigational drug candidate for dry eye disease.
📋 Key Facts
- Completion of enrollment in a Phase 3 clinical trial for reproxalap.
- The trial focuses on the treatment of dry eye disease.
- Announcement made via press release on June 13, 2024.
Aldeyra Therapeutics reported the results of its 2024 annual meeting of stockholders held on June 4, 2024. The meeting included the election of directors, ratification of the independent auditor, and an advisory vote on executive compensation.
🚩 Red Flags
- High number of withheld votes/broker non-votes in director elections suggests potential shareholder dissatisfaction with specific board candidates.
📋 Key Facts
- Annual Meeting held on June 4, 2024.
- Quorum was established with 44,659,863 shares (approx. 75.2%) represented out of 59,414,489 total voting shares.
- Nancy B. Miller-Rich and Ben R. Bronstein, M.D. were elected to the Board of Directors for Class I terms ending in 2027.
- Stockholders ratified the appointment of BDO USA, P.C. as independent auditors for fiscal year ending Dec 31, 2024.
- Stockholders approved executive compensation on a non-binding advisory basis (Say-on-Pay).
Aldeyra Therapeutics announced its intention to present a slide presentation at its 2024 Research & Development Day on April 25, 2024. The filing serves as a Regulation FD disclosure to provide summary information regarding the company's product candidates and clinical trial prospects.
🚩 Red Flags
- The filing contains extensive forward-looking statement disclaimers, highlighting risks related to clinical trial success, regulatory approval delays, and the need for additional financing.
📋 Key Facts
- The company held/is holding a 2024 Research & Development Day in New York City and via webcast on April 25, 2024.
- The presentation includes information regarding the goals and potential of reproxalap.
- The filing discusses clinical trial timelines and the status of FDA review/resubmission for reproxalap.
- Exhibits 99.1 (Slide Presentation) and 99.2 (Press Release) were furnished as part of this report.
Aldeyra Therapeutics issued an 8-K to furnish a press release containing a development plan update for its investigational drug candidate, reproxalap, intended for the treatment of dry eye disease.
📋 Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD Disclosure).
- The announcement concerns a development plan update for 'reproxalap'.
- Reproxalap is an investigational drug candidate for the treatment of dry eye disease.
- A press release was issued on March 28, 2024, to provide this update.
Aldeyra Therapeutics announced that its President and CEO will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The filing includes a presentation regarding the company's clinical and regulatory status.
📋 Key Facts
- CEO to participate virtually in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024.
- Discussion topic: Clinical and regulatory status of Aldeyra’s product candidates.
- The presentation is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Aldeyra Therapeutics issued an 8-K to provide a clinical and regulatory update via a press release. The filing does not contain specific financial or structural changes but serves as a vehicle for company news.
📋 Key Facts
- The filing is dated January 4, 2024.
- The primary purpose of the filing is to provide a clinical and regulatory update via Exhibit 99.1.
- No specific financial data or material agreements were disclosed in the text of the 8-K itself.